Kaleido Biosciences Inc expected to post a loss of 58  cents a share - Earnings Preview

Kaleido Biosciences

25/02/2022 12:02

* Kaleido Biosciences Inc  KLDO.OQ   KLDO.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 1
(estimated). 
    * The Bedford Massachusetts-based  company is expected to
report 
a 360.9% increase in revenue to $1.12 million from $243 thousand
a year ago, according to the mean estimate from 5 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Kaleido Biosciences
Inc
is for a loss of 58 cents per share. For the same quarter last
year, the company reported a loss of 56 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kaleido
Biosciences Inc is $4​, about 62.3% above​ its last closing
price of $1.51. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.53       -0.54      -0.54     Met     0.3
 Jun. 30 2021  -0.56       -0.57      -0.56     Beat    1.1
 Mar. 31 2021  -0.58       -0.59      -0.58     Beat    2.4​
 Dec. 31 2020  -0.49       -0.40      -0.56     Missed  -40.6
 ​​Sep.        -0.59       -0.63      -0.65     Missed  -2.5
 30 2020                                                
 Jun. 30 2020  -0.58       -0.59      -0.59     Met     0​
 Mar. 31 2020  -0.64       -0.64      -0.64     Met     0
 Dec. 31 2019              -0.34      -0.61     Missed  -80.7
 This summary was machine generated February 25 at 12:02 GMT. 
All figures in US dollars  unless otherwise stated